Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TNFRSF11B
REST API REST API
Homo sapiens
TNFRSF11B is differentially expressed in 260 experiments: 140 organism parts: kidney, liver, ... (138 more);, 145 disease states: normal, prostate carcinoma, ... (143 more);, 67 cell types 364 cell lines 33 compound treatments and 61 other conditions.
Synonyms TR1, OPG, OCIF
Orthologs TR11B_BOVIN (Bos taurus)   Tnfrsf11b (Mus musculus)   TNFRSF11B (Gallus gallus)   Tnfrsf11b (Rattus norvegicus)   XB-GENE-1005924 (Xenopus laevis)   TNFRSF11B (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, proteinaceous extracellular matrix, extracellular region, cytokine activity, response to nutrient, receptor activity, response to drug, binding, extracellular matrix organization, signal transduction, response to magnesium ion, response to estrogen stimulus, response to inorganic substance, negative regulation of bone resorption, skeletal system development, negative regulation of odontogenesis of dentine-containing tooth, response to arsenic-containing substance
InterPro Term TNFR_Cys_rich_reg, Death, TNFR_11B, TNFR_11
UniProt Accession O00300, E5RFV7
Gene-Disease Assocation PAGET DISEASE, JUVENILE
Search EB-eye ENSG00000164761
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
SW480
4
E-MTAB-37, E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-20089, E-GEOD-17482
BT-474
2
E-GEOD-3529, E-GEOD-5823
HCC2218
1
E-MTAB-37
358 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-13909, ... (34 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998
plasma cell
2
E-GEOD-6691, E-MEXP-2360
monocyte
2
E-GEOD-8286, E-MEXP-583
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
endothelial cell
2
E-GEOD-3920, E-GEOD-3998
fibroblast
1
2
E-GEOD-3920, E-MEXP-466, E-GEOD-3204
61 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-3860, E-GEOD-2508, E-GEOD-15960, E-MEXP-2069, ... (46 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-GEOD-96, E-MTAB-62, E-MTAB-37
prostate carcinoma
1
3
E-GEOD-96, E-MTAB-62, E-MEXP-2034, E-GEOD-3868
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
benign prostatic hyperplasia
2
E-GEOD-3868, E-MEXP-2034
acute promyelocytic leukemia
2
E-GEOD-96, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
139 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5679, E-GEOD-15205, E-GEOD-3720, ... (23 experiments)

Factor Value U/D Experiments
none
2
3
E-MEXP-1958, E-GEOD-5824, E-GEOD-412, E-GEOD-6431, E-GEOD-5418 ... (5 experiments)
mercury dichloride
1
E-GEOD-6907
rosiglitazone and AGN193109
1
E-GEOD-5679
heregulin
1
E-GEOD-6462
dimethyl sulfoxide
1
E-GEOD-5824
estradiol
1
E-GEOD-20081
27 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
117.12
1
1
E-TABM-325
91
1
1
E-TABM-325
101.34
1
E-TABM-325
126.19
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-21138, E-GEOD-19665, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-18736, E-TABM-868, E-TABM-601, E-GEOD-1153 ... (5 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-MEXP-1446, E-GEOD-19018, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-GEOD-2748

Treatment
studied in E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.434 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM